Patel Kirtesh R, Burri Stuart H, Asher Anthony L, Crocker Ian R, Fraser Robert W, Zhang Chao, Chen Zhengjia, Kandula Shravan, Zhong Jim, Press Robert H, Olson Jeffery J, Oyesiku Nelson M, Wait Scott D, Curran Walter J, Shu Hui-Kuo G, Prabhu Roshan S
*Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia; ‡Southeast Radiation Oncology Group, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina; §Carolina Neurosurgery and Spine Associates, Levine Cancer Institute, Charlotte, North Carolina; ¶Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia; ‖Department of Neurological Surgery, Emory University, Atlanta, Georgia.
Neurosurgery. 2016 Aug;79(2):279-85. doi: 10.1227/NEU.0000000000001096.
Stereotactic radiosurgery (SRS) is an increasingly common modality used with surgery for resectable brain metastases (BM).
To present a multi-institutional retrospective comparison of outcomes and toxicities of preoperative SRS (Pre-SRS) and postoperative SRS (Post-SRS).
We reviewed the records of patients who underwent resection of BM and either Pre-SRS or Post-SRS alone between 2005 and 2013 at 2 institutions. Pre-SRS used a dose-reduction strategy based on tumor size, with planned resection within 48 hours. Cumulative incidence with competing risks was used to determine estimated rates.
A total of 180 patients underwent surgical resection for 189 BM: 66 (36.7%) underwent Pre-SRS and 114 (63.3%) underwent Post-SRS. Baseline patient characteristics were balanced except for higher rates of performance status 0 (62.1% vs 28.9%, P < .001) and primary breast cancer (27.2% vs 10.5%, P = .010) for Pre-SRS. Pre-SRS had lower median planning target volume margin (0 mm vs 2 mm) and peripheral dose (14.5 Gy vs 18 Gy), but similar gross tumor volume (8.3 mL vs 9.2 mL, P = .85). The median imaging follow-up period was 24.6 months for alive patients. Multivariable analyses revealed no difference between groups for overall survival (P = .1), local recurrence (P = .24), and distant brain recurrence (P = .75). Post-SRS was associated with significantly higher rates of leptomeningeal disease (2 years: 16.6% vs 3.2%, P = .010) and symptomatic radiation necrosis (2 years: 16.4% vs 4.9%, P = .010).
Pre-SRS and Post-SRS for resected BM provide similarly favorable rates of local recurrence, distant brain recurrence, and overall survival, but with significantly lower rates of symptomatic radiation necrosis and leptomeningeal disease in the Pre-SRS cohort. A prospective clinical trial comparing these treatment approaches is warranted.
BM, brain metastasesCI, confidence intervalCTV, clinical target volumeDBR, distant brain recurrenceGTV, gross tumor volumeLC, local controlLMD, leptomeningeal diseaseLR, local recurrenceMVA, multivariable analysisOS, overall survivalPost-SRS, postoperative stereotactic radiosurgeryPre-SRS, preoperative stereotactic radiosurgeryPTV, planning target volumeRN, radiation necrosisSRN, symptomatic radiation necrosisSRS, stereotactic radiosurgeryWBRT, whole-brain radiation therapy.
立体定向放射外科(SRS)是一种越来越常用于可切除脑转移瘤(BM)手术治疗的方式。
对术前SRS(Pre-SRS)和术后SRS(Post-SRS)的疗效和毒性进行多机构回顾性比较。
我们回顾了2005年至2013年期间在2家机构接受BM切除术且单独接受Pre-SRS或Post-SRS治疗的患者记录。Pre-SRS采用基于肿瘤大小的剂量降低策略,计划在48小时内进行切除。采用竞争风险累积发病率来确定估计发生率。
共有180例患者因189个BM接受了手术切除:66例(36.7%)接受了Pre-SRS,114例(63.3%)接受了Post-SRS。除Pre-SRS组的0级功能状态发生率较高(62.1%对28.9%,P <.001)和原发性乳腺癌发生率较高(27.2%对10.5%,P =.010)外,基线患者特征保持平衡。Pre-SRS的中位计划靶体积边缘(0 mm对2 mm)和外周剂量(14.5 Gy对18 Gy)较低,但大体肿瘤体积相似(8.3 mL对9.2 mL,P =.85)。存活患者的中位影像随访期为24.6个月。多变量分析显示两组在总生存期(P =.1)、局部复发(P =.24)和远处脑复发(P =.75)方面无差异。Post-SRS与软脑膜疾病发生率显著较高相关(2年:16.6%对3.2%,P =.010)和有症状的放射性坏死发生率显著较高相关(2年:16.4%对4.9%,P =.010)。
切除性BM的Pre-SRS和Post-SRS在局部复发、远处脑复发和总生存期方面提供了相似的良好发生率,但Pre-SRS队列中有症状的放射性坏死和软脑膜疾病发生率显著较低。有必要进行一项比较这些治疗方法的前瞻性临床试验。
BM,脑转移瘤;CI,置信区间;CTV,临床靶体积;DBR,远处脑复发;GTV,大体肿瘤体积;LC,局部控制;LMD,软脑膜疾病;LR,局部复发;MVA,多变量分析;OS,总生存期;Post-SRS,术后立体定向放射外科;Pre-SRS,术前立体定向放射外科;PTV,计划靶体积;RN,放射性坏死;SRN,有症状的放射性坏死;SRS,立体定向放射外科;WBRT,全脑放射治疗